Previous close | 0.9200 |
Open | 0.5000 |
Bid | 0.5900 |
Ask | 0.7000 |
Strike | 28.00 |
Expiry date | 2024-05-17 |
Day's range | 0.5000 - 0.9200 |
Contract range | N/A |
Volume | |
Open interest | 32.9k |
The cost cuts are the latest move by the company to respond to slumping demand for its COVID-19 products after they powered it to report record revenues in 2021 and 2022. Pfizer's shares were up 2.6% at $29.3 in afternoon trading.
(Bloomberg) -- When Elliott Investment Management came calling for the ouster of Emma Walmsley, the chief executive officer of GSK Plc found her remedy in a product almost 60 years in the making.Most Read from BloombergOne Dead After Singapore Air Flight Hit By Severe TurbulenceASML, TSMC Can Disable Chip Machines If China Invades TaiwanHims Debuts $199 Weight-Loss Shots at 85% Discount to WegovyJamie Dimon Says Succession at JPMorgan Is ‘Well on the Way’Tesla Shareholder Group Slams Elon Musk’s
After disappointing sales for their Covid vaccines last year, drugmakers are hoping for an August rollout of the updated shot.